U.S. Food and Drug Administration reviewer David Graham told Congress that "at least five medications now sold to consumers pose such risks that their sale should be limited or stopped." They are the weight-loss drug Meridia, anti-cholesterol drug Crestor, acne drug Accutane, painkiller Bextra and asthma treatment Serevent. Pfizer [3] just retained Ogilvy PR [4] for its "pain franchise," which includes Bextra and Celebrex. "Pfizer's pain franchise has been subject to the same inquiries as Merck's Vioxx [5]," reports [6] PR Week. "Pfizer has already undertaken an advertising initiative for Celebrex to promote its safety."